Northwest Biotherapeutics (NWBO) Reports Q3 Loss of $0.35/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Northwest Biotherapeutics (NWBO) Reports $35M in Financing
November 19, 2014 3:38 PM ESTNorthwest Biotherapeutics (NASDAQ: NWBO) announced today two financings totaling $35 million. The financings include a $25 million equity investment by UK based C.F. Woodford Equity Income Fund ("Woodford"), and a $10 million mortgage on the Company's recently acquired UK facility.
Woodford purchased $25 million of unregistered shares of the Company's common stock at $5.79 per share, for a total of 4,317,790 shares. The Company agreed to undertake registration of the shares within the next couple of months.
"We are excited to have the UK's leading biotech investor come on board with NW Bio," commented... More
